Novo Nordisk is lowering the advertised U.S. prices for Ozempic (a diabetes drug) and Wegovy (a weight-loss drug) by as much as 50%. This is the company's move to make these expensive medications more affordable for patients and insurers.

• •Novo Nordisk to cut US list prices for Ozempic and Wegovy by up to 50%
• •Move targets affordability for patients and insurers

Novo Nordisk is giving its diabetes pill a new name in the United States—it will now be called Ozempic, the same name as the company's popular injectable weight-loss drug. This name change helps patients and doctors recognize that both the pill and injection contain the same active ingredient (semaglutide) and work the same way.

• •Novo Nordisk rebranding its oral diabetes tablet as Ozempic in the US
• •Pill and injection share semaglutide as active ingredient

Novo Nordisk has stopped selling Rybelsus, its oral semaglutide tablet, in the United States and is now calling semaglutide pills by the Ozempic brand name instead. This change makes the pill version match the name of the popular injection form.

• •Novo Nordisk has retired the Rybelsus brand in the US
• •Oral semaglutide will now be marketed under the Ozempic name
• •Move unifies pill and injection under a single brand

Novo Nordisk rebranded its oral semaglutide pill Rybelsus under the Ozempic name, aligning the product with its popular injection brand. Amgen reduced the size of its drug development pipeline.

• •Novo Nordisk rebranded oral semaglutide Rybelsus under the Ozempic name
• •Rebrand aligns the pill with Novo's injection franchise
• •Amgen reduced the size of its drug development pipeline

Novo Nordisk is expanding its GLP-1 drug portfolio by developing an oral version of Ozempic (semaglutide) and pushing into pediatric use. These moves aim to reach more patients with weight-loss and diabetes treatments beyond the current injectable forms.

• •Novo Nordisk developing oral version of Ozempic (semaglutide)
• •Novo pushing GLP-1 portfolio into pediatric use
• •Expansion targets weight-loss and diabetes beyond injectables